Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2020, with a specific reporting date of July 15, 2020. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. It exclusively details specific share transactions executed on July 13, 2020.
| Instrument | Transaction Price | Exchange | Transaction Date |
|---|---|---|---|
| Ordinary Shares (GBP) | £15.9280 | London Stock Exchange (XLON) | 2020-07-13 |
| American Depositary Shares (USD) | $40.3700 | New York Stock Exchange (XNYS) | 2020-07-13 |
Material Changes
The filing reports an increase in the notional interest of various executives in GSK Ordinary Shares and ADSs. These increases resulted from the re-investment of dividends paid to shareholders on July 9, 2020, under the Company's Deferred Annual Bonus Plan. There are no material changes to the company's financial position or operations reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly a regulatory disclosure of specific share transactions.
Important Facts for Investors
- Transaction Nature: All reported transactions were automatic re-investments of dividends into the Deferred Annual Bonus Plan, not discretionary purchases or sales by executives.
- Participants: Transactions involved senior leadership including the CEO (Ms E Walmsley), CFO (Mr I Mackay), Chief Scientific Officer (Dr H Barron), and other SVPs.
- Share Prices: The transactions reflect a share price of £15.9280 for Ordinary Shares and $40.3700 for ADSs on July 13, 2020.
- Volume: Individual transaction volumes were relatively small, ranging from 39 to 812 shares/ADSs per executive.
- Limitations: This filing does not provide data on GSK's overall financial performance, revenue, or earnings for the period.